Relationship Between Clinical Prognosis and Expression of P_(170) and CD_(34) in Patients With Preliminary Diagnostic Acute Myeloblastic Leukemia / 中国医师杂志

Objective To observe the expression and the clinical significance of P 170 and CD 34 in primary acute myeloblastic leukemia (AML)patients.Methods The expression of P 170 and CD 34 was determined by flow cytometry in 30 AML patients.Results The P 170 positive rate was 36.67%,the patients with the P 170 positive expression had higher resistant rate to chemotherapy as compared with P 170 negative group(P

Construction of pLNCX/anti-CD20scFv/IgGFc/CD80/CD28/? eukaryotic expression vector and expression in NIH 3T3 cells / 中国病理生理杂志

AIM:To construct a recombinant eukaryotic expression vector pLNCX/anti-CD20scFv/IgGFc/CD80/CD28/? and detect its expression in NIH 3T3 cells.METHODS:CD28-? cDNA was amplified from the plasmids pBULLET and inserted into pLNCX vector that contained anti-CD20 scFv/IgGFc/CD80 gene.The recombinant plasmids were transfected into NIH 3T3 cells,and resistant clones were obtained by G418 selection.The gene expression of the fusion protein was determined by RT-PCR and FACS.RESULTS:The recombinant eukaryotic vector was constructed successfully,determined by PCR and enzyme digestion analysis.The target gene was amplified from NIH 3T3 cells transfected with the vectors by RT-PCR.The FACS showed that recombinant protein was expressed in NIH 3T3 cells.CONCLUSION:Construction of pLNCX/anti-CD20scFv/IgGFc/CD80/CD28/? expression vector and its expression in NIH 3T3 cells lay the foundation for further research of generation of modified T lymphocytes to CD20 positive lymphoma.